Response of Rat Thoracic Aorta to F2-Isoprostane Metabolites

This study was undertaken to investigate the vascular actions (contraction and relaxation) of the F2-isoprostane metabolites 15-keto-15-F2t-IsoP, 2,3-dinor-15-F2t-IsoP, and 2,3-dinor-5,6-dihydro -15-F2t-IsoP in comparison with 15-F2t-IsoP on the rat thoracic aorta. 15-keto-15-F2t-IsoP induced a vasoconstriction in a concentration-dependent manner with a pD2 value of 5.80 ± 0.05, whereas 2,3-dinor-15-F2t-IsoP and 2,3-dinor-5,6-dihydro-15-F2t-IsoP had no effect. The parent compound 15-F2t-IsoP was more potent (pD2 value: 6.46 ± 0.1). Endothelium removal had no influence on the contraction to 15-keto-15-F2t-IsoP. GR32191 (a TP-receptor antagonist) concentration-dependently inhibited the contraction induced by 15-keto-15-F2t-IsoP, with a significant decrease in the Emax values for GR32191 10−7M. Pretreatment with 2,3-dinor-15-F2t-IsoP and 2,3-dinor-5,6-dihydro-15-F2t-IsoP induced no alteration of 15-F2t-IsoP concentration-response curves. In contrast, 15-keto-15-F2t-IsoP pretreatment competitively inhibited the response to 15-F2t-IsoP. When concentration ratios of EC50 values were used, a Schild regression of this data was linear with a slope of 0.974 and a pA2 value of 6.13. 15-keto-15-F2t-IsoP at high concentrations caused a weak concentration-dependent relaxation of rat aorta rings contracted with U46619 (3.10−8M) that was not modified in the absence of endothelium. In contrast, 2,3-dinor-15-F2t-IsoP and 2,3-dinor-5,6-dihydro-15-F2t-IsoP induced no vasodilation. In conclusion, among the F2-isoprostane metabolites, 2,3-dinor-15-F2t-IsoP and 2,3-dinor-5,6-dihydro-15-F2t-IsoP did not cause vasorelaxation or vasoconstriction on the rat thoracic aorta. In contrast, 15-keto-15-F2t-IsoP mediates contraction through activation of TP-receptors, probably as a partial agonist, and induces a weak endothelium-independent relaxation at high concentrations.

[1]  P. Devillier,et al.  Vascular Biology of the Isoprostanes , 2001, Journal of Vascular Research.

[2]  T. Durand,et al.  Total Syntheses of Four Metabolites of 15‐F2t‐Isoprostane , 2001 .

[3]  G. FitzGerald,et al.  Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo , 2000 .

[4]  T. Durand,et al.  Total synthesis of 4(RS)-F4t-isoprostane methyl ester , 2000 .

[5]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[6]  G. FitzGerald,et al.  Specific Analysis in Plasma and Urine of 2,3-Dinor-5,6-dihydro-isoprostane F2α-III, a Metabolite of Isoprostane F2α-III and an Oxidation Product of γ-Linolenic Acid* , 2000, The Journal of Biological Chemistry.

[7]  L. Lerman,et al.  Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. , 1999, Cardiovascular research.

[8]  R. Fanelli,et al.  Identification and Measurement of Endogenous β-Oxidation Metabolites of 8-epi-Prostaglandin F2α* , 1999, The Journal of Biological Chemistry.

[9]  T. Montine,et al.  Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid* , 1998, The Journal of Biological Chemistry.

[10]  S. Basu,et al.  Metabolism of 8‐iso‐prostaglandin F2α , 1998 .

[11]  G. FitzGerald,et al.  Nomenclature of isoprostanes: a proposal. , 1997, Prostaglandins.

[12]  E. Anggard,et al.  Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. , 1997, Biochemical and biophysical research communications.

[13]  T. Evans,et al.  Evidence for a dilator function of 8‐iso prostaglandin F2α in rat pulmonary artery , 1997 .

[14]  J. Morrow,et al.  A nomenclature system for the isoprostanes. , 1997, Prostaglandins.

[15]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.

[16]  B. Kromer,et al.  Coronary artery constriction by the isoprostane 8‐epi prostaglandin F2α , 1996, British journal of pharmacology.

[17]  J. Morrow,et al.  Identification of the Major Urinary Metabolite of the F2-isoprostane 8-Iso-prostaglandin F2α in Humans* , 1996, The Journal of Biological Chemistry.

[18]  E. Hellström‐Lindahl,et al.  Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor , 1994 .

[19]  Y. Boie,et al.  Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.

[20]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. P. White,et al.  GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro , 1989, British journal of pharmacology.

[22]  R. A. Coleman,et al.  COMPARISON OF THE ACTIONS OF U‐46619, A PROSTAGLANDIN H2‐ANALOGUE, WITH THOSE OF PROSTAGLANDIN H2 AND THROMBOXANE A2 ON SOME ISOLATED SMOOTH MUSCLE PREPARATIONS , 1981, British journal of pharmacology.

[23]  P. Devillier,et al.  Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. , 2001, Cardiovascular research.

[24]  G. FitzGerald,et al.  Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid. , 2000, The Journal of biological chemistry.

[25]  Y. Boie,et al.  Cloning and expression of a cDNA for the human prostanoid FP receptor. , 1994, The Journal of biological chemistry.

[26]  E. Hornby,et al.  Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. , 1990, Circulation.